PDCD1 and lung carcinoma: However, the clinical response of patients with EOC to treatment with the immune checkpoint inhibitors PD-1 or PD-L1 has been modest in comparison with the robust response observed in melanoma, lung cancer, and renal cell cancer (5, 14).